The drug acts as a neuro-protective agent and prevents apoptosis of retinal ganglion cells
Raxone (idebenone), a synthetic short-chain benzoquinone and a cofactor for the enzyme NAD(P)H:quinone oxidoreductase (NQO1), is capable of transferring electrons directly onto complex III of the mitochondrial electron transport chain, thereby circumventing the complex I defect, reducing and scavenging ROS and restoring cellular energy levels in retinal ganglion cells
and promoting recovery of visual acuity.
Oxidative stress is an early event in hydrostatic pressure induced retinal ganglion cell
The inner nuclear layer had a 37 percent loss of neurons and the retinal ganglion cell
layer a 49 percent loss, compared with healthy, age-matched control mice.
During the experiment, researchers noticed a loss of thickness in both the inner nuclear layer (37 percent) and the retinal ganglion cell
layer (49 percent) in the animals with the brain disease, compared to healthy mice.
Taurine provides neuroprotection against retinal ganglion cell
Retinal ganglion cells
(RGC) are born in a central to peripheral gradient.
Theories were proposed in the mid-1990s that particular subsets of retinal ganglion cells
were preferentially damaged in glaucoma, (20-22) along with the idea that glaucoma might be detected earlier if it were possible to isolate and measure their function.
The study authors suspect that the pronounced lack of balance control in the subjects with glaucoma may be related to the loss of retinal ganglion cells
caused by the disease, which leads to slower visual processing and impaired motion perception.
But mice that received the preconditioning before glaucoma-inducing surgery lost only 3 percent of retinal ganglion cell
NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging, announced today that Kenneth Shindler, MD, PhD, University of Pennsylvania Scheie Eye Institute in Philadelphia, will present preclinical data at the North American Neuro-Ophthalmology Society annual meeting showing that SRT501, when orally administered, slows retinal ganglion cell
loss during optic neuritis, a neurodegenerative eye disorder, and suppresses neurological dysfunction in a preclinical model of Multiple Sclerosis.
In the absence of optic neuritis, RNFL loss could result from retrograde trans-synaptic retinal ganglion cell
degeneration due to lesions in posterior optic pathways.